Hepatitis C Direct Acting Antivirals: The New Standard of Care, An Issue of Clinics in Liver Disease - Fred Poordad

Hepatitis C Direct Acting Antivirals: The New Standard of Care, An Issue of Clinics in Liver Disease

(Autor)

Buch | Hardcover
2011
W B Saunders Co Ltd (Verlag)
978-1-4557-1107-9 (ISBN)
78,55 inkl. MwSt
Hepatitis C Virus is a quickly evolving area within hepatology owing to various medical therapies. This title includes review articles devoted to the following medical therapies: Boceprevir, Telaprevir, Protease Inhibitors in Development, NS5B Nucleoside and Non-Nucleoside Inhibitors.
Hepatitis C Virus is a quickly evolving area within hepatology owing to new medical therapies. This issue, guest edited by Dr. Fred Poordad, includes the most current clinical information and treatment therapies. Expert authors have written review articles devoted to the following medical therapies: Boceprevir, Telaprevir, Protease Inhibitors in Development, NS5B Nucleoside and Non-Nucleoside Inhibitors. Review articles also address important patients like naïve- and non-responders and relapsers, the HIV co-infected patient, and the Genotype 1 and non-Genotype 1 patient.
Erscheint lt. Verlag 22.12.2011
Reihe/Serie The Clinics: Internal Medicine
Zusatzinfo Illustrations
Verlagsort London
Sprache englisch
Maße 152 x 229 mm
Gewicht 460 g
Themenwelt Medizinische Fachgebiete Innere Medizin Hepatologie
ISBN-10 1-4557-1107-1 / 1455711071
ISBN-13 978-1-4557-1107-9 / 9781455711079
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
Diagnostik, Differenzialdiagnostik, Therapieansätze

von Frank Fischbach; Katharina Fischbach

Buch (2016)
Thieme (Verlag)
101,00